The stock of Bioline Rx Ltd ADR (NASDAQ: BLRX) has increased by 3.28 when compared to last closing price of 0.22. Despite this, the company has experienced a 10.10% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-25 that BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey – Head of IR & Corporate Communications Phil Serlin – CEO Mali Zeevi – CFO Conference Call Participants Joe Pantginis – HC Wainwright Justin Walsh – Jones Trading John Vandermosten – Zacks Operator Ladies and gentlemen, thank you for standing by.
Is It Worth Investing in Bioline Rx Ltd ADR (NASDAQ: BLRX) Right Now?
Company’s 36-month beta value is 1.44.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLRX is 86.63M, and currently, short sellers hold a 1.06% ratio of that floaft. The average trading volume of BLRX on December 24, 2024 was 1.00M shares.
BLRX’s Market Performance
The stock of Bioline Rx Ltd ADR (BLRX) has seen a 10.10% increase in the past week, with a -17.26% drop in the past month, and a -64.05% fall in the past quarter. The volatility ratio for the week is 8.63%, and the volatility levels for the past 30 days are at 10.96% for BLRX. The simple moving average for the last 20 days is -5.25% for BLRX stock, with a simple moving average of -62.97% for the last 200 days.
Analysts’ Opinion of BLRX
Many brokerage firms have already submitted their reports for BLRX stocks, with Maxim Group repeating the rating for BLRX by listing it as a “Buy.” The predicted price for BLRX in the upcoming period, according to Maxim Group is $3 based on the research report published on May 18, 2017 of the previous year 2017.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see BLRX reach a price target of $3. The rating they have provided for BLRX stocks is “Buy” according to the report published on February 13th, 2017.
Maxim Group gave a rating of “Hold” to BLRX, setting the target price at $1 in the report published on August 12th of the previous year.
BLRX Trading at -35.65% from the 50-Day Moving Average
After a stumble in the market that brought BLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.97% of loss for the given period.
Volatility was left at 10.96%, however, over the last 30 days, the volatility rate increased by 8.63%, as shares sank -14.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.40% lower at present.
During the last 5 trading sessions, BLRX rose by +11.48%, which changed the moving average for the period of 200-days by -79.56% in comparison to the 20-day moving average, which settled at $0.2430. In addition, Bioline Rx Ltd ADR saw -85.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BLRX
Current profitability levels for the company are sitting at:
- -1.57 for the present operating margin
- 0.69 for the gross margin
The net margin for Bioline Rx Ltd ADR stands at -0.91. The total capital return value is set at -1.24. Equity return is now at value -184.09, with -37.72 for asset returns.
Based on Bioline Rx Ltd ADR (BLRX), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at 3.27. The interest coverage ratio of the stock is -7.41.
Currently, EBITDA for the company is -57.06 million with net debt to EBITDA at -1.56. When we switch over and look at the enterprise to sales, we see a ratio of 2.05. The receivables turnover for the company is 5.55for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
In a nutshell, Bioline Rx Ltd ADR (BLRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
